Journal of the European Academy of Dermatology and Venereology

Article	Citations
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children	255
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations	182
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy	161
Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience	150
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations	106
European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II	104
European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations	103
Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel	100
UpdatedS2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)	97
2021 European guideline on the management of Mycoplasma genitalium infections	91
Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis	79
Common causes of hair loss – clinical manifestations, trichoscopy and therapy	78
Prevalence of most common skin diseases in Europe: a population‐based study	75
European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I	73
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study	72
The first dose of COVID‐19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?	70
Lichen planus arising after COVID‐19 vaccination	68
Line‐field confocal optical coherence tomography of basal cell carcinoma: a descriptive study	67
3D wide‐field multispectral photoacoustic imaging of human melanomas in vivo: a pilot study	67
Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic	66
Psoriasis exacerbation after COVID‐19 vaccination: a report of 14 cases from a single centre	63
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled t	63
A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy	61
Transient cutaneous manifestations after administration of Pfizer‐BioNTech COVID‐19 Vaccine: an Italian single‐centre case series	59
Development of severe pemphigus vulgaris following SARS‐CoV‐2 vaccination with BNT162b2	59

Skin manifestations of the BNT162b2 mRNA COVID‐19 vaccine in healthcare workers. ‘COVID‐arm’: a clinical and histological characterization	56
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis	55
Varicella‐zoster and herpes simplex virus reactivation post‐COVID‐19 vaccination: a review of 40 cases in an International Dermatology Registry	54
New‐onset cutaneous lichen planus triggered by COVID‐19 vaccination	53
Epidermal thickness in healthy humans: a systematic review and meta‐analysis	53
SARS‐CoV‐2‐induced telogen effluvium: a multicentric study	51
Adult skin acute stress responses to short‐term environmental and internal aggression from exposome factors	49
Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from Northeast Italy	48
Epidemiological and clinical aspects of Trichophyton mentagrophytes/Trichophyton interdigitale infections in the Zurich area: a retrospective study using genotyping	47
Stigma in visible skin diseases – a literature review and development of a conceptual model	47
Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA	46
European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement	46
A systematic review of worldwide data on tinea capitis: analysis of the last 20 years	45
Prompt onset of Rowell's syndrome following the first BNT162b2 SARS‐CoV‐2 vaccination	45
Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review	43
Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?	43
Pityriasis rosea‐like eruptions following vaccination with BNT162b2 mRNA COVID‐19 Vaccine	42
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD	41
Skin adverse events related to personal protective equipment: a systematic review and meta‐analysis	41
Psoriasis flare‐up associated with second dose of Pfizer‐BioNTech BNT16B2b2 COVID‐19 mRNA vaccine	41
Performance of a deep neural network in teledermatology: a single‐centre prospective diagnostic study	40
Monkeypox virus case with maculopapular exanthem and proctitis during the Spanish outbreak in 2022	40
Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial	40
Persistent maculopapular rash after the first dose of Pfizer‐BioNTech COVID‐19 vaccine	39
2021 European Guideline on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens	39
Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options	39
Line‐field confocal optical coherence tomography of psoriasis, eczema and lichen planus: a case series with histopathological correlation	38
Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real‐life experience	38
Wound healing and microbiome, an unexpected relationship	38
Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose	38
Incidence of pemphigoid diseases in Northern Germany in 2016 – first data from the Schleswig‐Holstein Registry of Autoimmune Bullous Diseases	38
S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)	37
Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting	36
Expert consensus on the systemic treatment of atopic dermatitis in special populations	36
Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review	36
The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity	36
Reply to “Psoriasis exacerbation after COVID‐19 vaccination: report of 14 cases from a single centre” by Sotiriou E et al.	36
A machine learning‐based, decision support, mobile phone application for diagnosis of common dermatological diseases	36
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study	34
Is Scabies becoming less sensitive to permethrin therapy?	34
Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID‐19 vaccine	34
Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany	33
Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed Th2 immunity	33
The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis – A network meta‐analysis	33
Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: A systematic review and meta‐analysis	32
New onset of mainly guttate psoriasis after COVID‐19 vaccination: a case report	32
Real‐world evidence from over one million COVID‐19 vaccinations is consistent with reactivation of the varicella‐zoster virus	32
5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia	32
Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase	32
Intravenous allogeneic multilineage‐differentiating stress‐enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1/2 open‐label study	31

Line‐field confocal optical coherence tomography for the in vivo real‐time diagnosis of different stages of keratinocyte skin cancer: a preliminary study	31
The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non‐lesional skin	31
Reply to ‘Cutaneous adverse effects of the available COVID‐19 vaccines in India: A questionnaire‐based study’ by Bawane J et al.	30
De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort	30
Reply to ‘Development of severe pemphigus vulgaris following SARS‐CoV‐2 vaccination with BNT162b2’ by Solimani et al.	30
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic	30
Atopic dermatitis exacerbation after Covid‐19 vaccination in Dupilumab‐treated patients	29
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management	29
Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome	29
Pruritus Intensity Scales across Europe: a prospective validation study	29
Complete blood collection‐based systemic inflammation biomarkers for patients with hidradenitis suppurativa	29
Continuous glucose monitoring systems give contact dermatitis in children and adults despite efforts of providing less ‘allergy‐ prone’ devices: investigation and advice hampered by insufficient mater	29
Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis	29
Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib	29
Development of oral lichen planus after COVID‐19 vaccination – a rare case report	29
Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID‐19 vaccine: another piece of SARS‐CoV‐2 skin puzzle?	28
Clinical symptoms of hyperandrogenic women diagnosed with COVID‐19	28
European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics	28
BNT162b2 mRNA COVID‐19 vaccine‐induced chilblain‐like lesions reinforces the hypothesis of their relationship with SARS‐CoV‐2	28
Development and validation of IHS4‐55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa	28
Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford–AstraZeneca COVID‐19 vaccine: report of three cases from India	28
Incidence of occupational contact dermatitis in healthcare workers: a systematic review	28
Pityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance	28
Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature	28
Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator‐blinded, randomized controlled trial	27
Nondermatophyte mould onychomycosis	27
GBP5 exacerbates rosacea‐like skin inflammation by skewing macrophage polarization towards M1 phenotype through the NF‐κB signalling pathway	27
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb ran	27
Image‐based automated Psoriasis Area Severity Index scoring by Convolutional Neural Networks	27
Moderate‐to‐severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real‐world experience	27
Recurrence of cutaneous T‐cell lymphoma post viral vector COVID‐19 vaccination	27
Psoriasis may increase the risk of lung cancer: a two‐sample Mendelian randomization study	27
Adverse skin reactions following different types of mask usage during the COVID‐19 pandemic	26
Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases – a systematic review	26
Improved protection of outdoor workers from solar ultraviolet radiation: position statement	26
Herpes zoster after ChAdOx1 nCoV‐19 vaccine: a case series	26
Neurokinin‐1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial	25
Update of advanced cutaneous squamous cell carcinoma	25
IgE autoantibodies in serum and skin of non‐bullous and bullous pemphigoid patients	25
A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of	24
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)	24
Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendations	24
Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances	24
New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare‐up after Sars‐Cov‐2 vaccination	24
Pityriasis rosea developing after COVID‐19 vaccination	24
Herpes Zoster following SARS‐CoV‐2 vaccination – a series of four cases	24
Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes	24
Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics	24
Prevalence and characteristics of atopic dermatitis among young adult females and males—report from the Swedish population‐based study BAMSE	24
Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)	24
Skin reaction after SARS‐CoV‐2 vaccines Reply to ‘cutaneous adverse reactions following SARS‐CoV‐2 vaccine booster dose: A real‐life multicentre experience’	24
Formulation of a new broad‐spectrum UVB + UVA and blue light SPF50+ sunscreen containing Phenylene Bis‐Diphenyltriazine (TriAsorB), an	24
Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes	24
Increased expression profile of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa	23
Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic	23
Transition of cutaneous into systemic lupus erythematosus following adenoviral vector‐based SARS‐CoV‐2 vaccination	23
Reactive granulomatous dermatitis as a histological pattern including manifestations of interstitial granulomatous dermatitis and palisaded neutrophilic and granulomatous dermatitis: a study of 52 pat	23
Artificial Intelligence analysis of over half a million European and Chinese women reveals striking differences in the facial skin ageing process	23
Therapeutic management in paediatric alopecia areata: A systematic review	23
Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm	22
Cutaneous adverse reactions following SARS‐CoV‐2 vaccine booster dose: a real‐life multicentre experience	22
A case of bullous pemphigoid after the SARS‐CoV‐2 mRNA vaccine	22
Impact of the French COVID‐19 pandemic lockdown on newly diagnosed melanoma delay and severity	22
First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis	22
Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population‐based claims data analysis	22
Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts	22
Position statement: The need for EU legislation to require disclosure and labelling of the composition of medical devices	22
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID‐19 vaccine, successfully treated with risankizumab	22
Topical therapy of atopic dermatitis with a focus on pimecrolimus	22
Distinctive clinical and histological characteristics of atrophic and hypertrophic facial photoageing	21
Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT	21
Unmet clinical needs and burden of disease in hidradenitis suppurativa: real‐world experience from EU5 and US	21
Cost‐of‐illness of atopic dermatitis in Germany: data from dermatology routine care	21
Comparison of Secukinumab and Ixekizumab in psoriasis: a real‐life cohort study on the efficacy and drug survival of 445 patients	21
Attenuation of intrinsic ageing of the skin via elimination of senescent dermal fibroblasts with senolytic drugs	21
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas	21
Primary alterations during the development of hidradenitis suppurativa	21
Chilblain‐like lesions and COVID‐19: second wave, second outbreak	20
Apremilast effectively inhibits TNFα‐induced vascular inflammation in human endothelial cells	20
SARS‐CoV‐2 spike protein is present in both endothelial and eccrine cells of a chilblain‐like skin lesion	20

S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)	20
Bifocal 532/1064 nm alternately illuminated photoacoustic microscopy for capturing deep vascular morphology in human skin	20
Clinicopathological features of cutaneous reactions after mRNA‐based COVID‐19 vaccines	20
COVID vaccine‐induced lichen planus on areas previously affected by vitiligo	20
Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial	20
Reliable and rapid identification of terbinafine resistance in dermatophytic nail and skin infections	20
Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases	20
Significance of chronic pruritus for intrapersonal burden and interpersonal experiences of stigmatization and sexuality in patients with psoriasis	20
Spesolimab, an anti‐interleukin‐36 receptor antibody, in patients with moderate‐to‐severe atopic dermatitis: Results from a multicentre, randomized, double‐blind, placebo‐controlled, phase IIa	20
Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN	20
Efficacy and prognostic factors of adjuvant radiotherapy for cutaneous squamous cell carcinoma: A systematic review and meta‐analysis	20
Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017	20
Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge‐proven food allergy: A systematic review and meta‐analysis	20
Pityriasis rosea following CoronaVac COVID‐19 vaccination: a case report	20
Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real‐life study	20
Prevalence and factors associated with sleep disturbance in adult patients with psoriasis	19
Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10‐year follow‐up at a tertiary centre	19
SARS‐CoV‐2 mRNA vaccine‐associated fixed drug eruption	19
Impact of the COVID‐19 pandemic on melanoma diagnosis	19
Unveiling the true costs and societal impacts of moderate‐to‐severe atopic dermatitis in Europe	19
The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes	19
Herpes zoster after inactivated SARS‐CoV‐2 vaccine in two healthy young adults	19
Real‐world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single‐centre, prospective, open‐label study	19
Rare cutaneous adverse effects of COVID‐19 vaccines: a case series and review of the literature	19
Chilblain‐like lesions after BNT162b2 mRNA COVID‐19 vaccine: a case report suggesting that ‘COVID toes’ are due to the immune reaction to SARS‐CoV‐2	19
A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis	19
Trichomonas vaginalis and growing concern over drug resistance: a systematic review	19
Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence	19
Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation	19
Prevalence and characterization of treatment‐refractory psoriasis and super‐responders to biologic treatment: a nationwide study	19
Full exome sequencing of 11 families with Hidradenitis suppurativa	19
Scabies is becoming less sensitive to permethrin therapy	19
Prevention and screening of melanoma in Europe: 20 years of the Euromelanoma campaign	19
Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines	19
The impact of the COVID‐19 pandemic on keratinocyte carcinoma in the Netherlands: Trends in diagnoses and magnitude of diagnostic delays	19
Real‐life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis	19
Line‐field confocal optical coherence tomography: a novel, non‐invasive imaging technique for a rapid, in‐vivo diagnosis of herpes infection of the skin	19
Global publication productivity in dermatology: a bibliometric description of the past and estimation of the future	19
Dupilumab‐associated hypereosinophilia in patients treated for moderate‐to‐severe atopic dermatitis	18
Potential applications of ChatGPT in dermatology	18
Epidemiology of inherited epidermolysis bullosa in Germany	18
Porokeratosis is one of the most common genodermatoses and is associated with an increased risk of keratinocyte cancer and melanoma	18
Potential role of INTERLEUKIN‐17 in the pathogenesis of oral lichen planus: a systematic review with META‐analysis	18
Requirements and expectations of high‐quality biomarkers for atopic dermatitis and psoriasis in 2021—a two‐round Delphi survey among international experts	18
2021 European guideline for the management of vulval conditions	18
New‐onset and exacerbations of psoriasis after mRNA COVID‐19 vaccines: two sides of the same coin?	18
Generalized eczematous reactions to the Pfizer‐BioNTech COVID‐19 vaccine	18
Small‐vessel vasculitis following Oxford‐AstraZeneca vaccination against SARS‐CoV‐2	18
Systematic review of single and combined treatments for different types of striae: a comparison of striae treatments	18
Dynamic optical coherence tomography shows characteristic alterations of blood vessels in malignant melanoma	18
Line‐field confocal optical coherence tomography: a new tool for non‐invasive differential diagnosis of pustular skin disorders	17
Trichodysplasia spinulosa: a comprehensive review of the disease and its treatment	17
Pfizer‐BioNTech SARS‐CoV‐2 mRNA vaccine‐associated erythema multiforme	17
Psoriasis flare‐up after AZD1222 and BNT162b2 COVID‐19 mRNA vaccines: report of twelve cases from a single centre	17
Dermoscopy of porokeratosis: results from a multicentre study of the International Dermoscopy Society	17
Clinical, biological and histological characteristics of bullous pemphigoid associated with anti‐PD‐1/PD‐L1 therapy: A national retrospective study	17
2021 international consensus statement on optical coherence tomography for basal cell carcinoma: image characteristics, terminology and educational needs	17
Scabies itch: an update on neuroimmune interactions and novel targets	17
Sociodemographic, clinical, laboratory, treatment and prognostic characteristics of 156 generalized pustular psoriasis patients in Turkey: a multicentre case series	17
The burden of neurological comorbidities in six autoimmune bullous diseases: a population‐based study	17
Describing the burden of the COVID‐19 pandemic in people with psoriasis: findings from a global cross‐sectional study	17
Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis	17
Epidemiology of advanced cutaneous squamous cell carcinoma	17
Pityriasis rosea as a leading manifestation of COVID‐19 infection	17
Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co‐morbidities	17
Methylated miRNAsmay serve as potential biomarkers and therapeutic targets for hidradenitis suppurativa	17
Dysbiosis of skin microbiota with increased fungal diversity is associated with severity of disease in atopic dermatitis	17
Three‐dimensional histology vs. serial section histology in the treatment of primary basal cell carcinoma: a randomized, prospective, blinded study of 569 tumours	17
Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real‐world results from the HARMONY Study	17
Recent advances in understanding inflammatory acne: Deciphering the relationship betweenCutibacterium acnesand Th17 inflammatory pathway	16
Generalized erythema multiforme‐like skin rash following the first dose of COVID‐19 vaccine (Pfizer‐BioNTech)	16
Assessing the dynamic changes in vitiligo: reliability and validity of the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS)	16
Evolution of the facial skin microbiome during puberty in normal and acne skin	16
Real‐world effectiveness of adalimumab in patients with moderate‐to‐severe hidradenitis suppurativa: the 1‐year SOLACE study	16
Rosacea, an infectious disease: why rosacea with papulopustules should be considered a demodicosis. A narrative review	16
Primary cutaneous peripheral T‐cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on	16
Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID‐19 vaccination: a prospective cohort study in healthcare workers	16
Atopic dermatitis and risk of major neuropsychiatric disorders in children: A population‐based cohort study	16
Line‐field confocal optical coherence tomography of basosquamous carcinoma: a case series with histopathological correlation	16
Pityriasis rubra pilaris after Vaxzevria® COVID‐19 vaccine	16
Systemic drug‐related intertriginous and flexural exanthema like eruption after CoronaVac vaccine	16
COVID‐19‐triggered sarcoidal granulomas mimicking scar sarcoidosis	16
Oral gliadin‐protected superoxide dismutase in addition to phototherapy for treating non‐segmental vitiligo: A 24‐week prospective randomized placebo‐controlled study	16
Actinic cheilitis: a systematic review of treatment options	16
The role of HPV in keratinocyte skin cancer development: A systematic review	16
Spesolimab improves patient‐reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study	16
	16
Erythema nodosum following the first dose of ChAdOx1‐S nCoV‐19 vaccine	16
Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real‐world evidence study	16
Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial	16
As monkeypox goes sexual: a public health perspective	15
A 52‐week update of a multicentre real‐life experience on effectiveness and safety of risankizumab in psoriasis	15
Treatment of keloids and hypertrophic scars. Position statement of the Brazilian expert group GREMCIQ	15
Tralokinumab in the treatment of resistant atopic dermatitis: An open‐label, retrospective case series study	15
The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid	15